title: A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.
abstract: Tissue- and device-associated biofilm infections are important medical problems. These infections are difficult to treat due to a high-level of tolerance to antibiotics. Telavancin has been studied in several in vitro biofilm models and has demonstrated efficacy against staphylococcal and enterococcal-associated biofilm infections, including those formed by methicillin-resistant Staphylococcus aureus. Telavancin was effective against the difficult-to-treat vancomycin- and glycopeptide-intermediate strains of S. aureus in these models. Furthermore, the efficacy of telavancin has been evaluated in several biofilm-related in vivo models, including osteomyelitis, endocarditis and device-associated infections in rabbits. Overall, telavancin exhibited similar or greater efficacy than vancomycin and other comparators in these animal models and maintained activity against vancomycin-intermediate and daptomycin nonsusceptible strains of S. aureus.
authors.affiliation: Theravance Biopharma US, Inc. 901 Gateway Blvd, South San Francisco, CA 94080, USA.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Chan
authors.affiliation: Theravance Biopharma US, Inc. 901 Gateway Blvd, South San Francisco, CA 94080, USA.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Hardin
authors.affiliation: Theravance Biopharma US, Inc. 901 Gateway Blvd, South San Francisco, CA 94080, USA.
authors.forename: Jennifer I
authors.initials: JI
authors.lastname: Smart
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D004195:Disease Models, Animal; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D016983:Enterococcus / Q000187:drug effects; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D010019:Osteomyelitis / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin
keywords: biofilm; device-associated infections; endocarditis; osteomyelitis; telavancin